This Article Abstract Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shiiya, T. Articles by Matsukura, S. Search for Related Content PubMed PubMed Citation Articles by Shiiya, T. Articles by Matsukura, S.

Plasma Ghrelin Levels in Lean and Obese Humans and the Effect of Glucose on Ghrelin Secretion

Department of Internal Medicine, Miyazaki Medical College (T.S., M.N., M.M., Y.D., M.S.M., S.M.), Miyazaki 889-1692, Japan; National Cardiovascular Center Research Institute (H.H., K.K.), Osaka 565-8565, Japan; and Department of Psychosomatic Medicine, Kagoshima University School of Medicine (M.T., S.N.), Kagoshima 890-8520, Japan

Address all correspondence and requests for reprints to: Masamitsu Nakazato, M.D., Ph.D., Third Department of Internal Medicine, Miyazaki Medical College, Kiyotake, Miyazaki 889-1692, Japan. E-mail: nakazato{at}post.miyazaki-med.ac.jp

	Abstract

Top Abstract Introduction Subjects and Methods Results Discussion References

 
Ghrelin, a novel GH-releasing peptide isolated from human and rat stomach, stimulates food intake and GH secretion. We determined plasma ghrelin concentrations in patients with simple obesity, anorexia nervosa, and type 2 diabetes mellitus by RIA. We also studied plasma ghrelin responses to glucose load and meal intake and obtained a 24-h profile of circulating ghrelin in humans.

Plasma ghrelin concentrations in patients with simple obesity and anorexia nervosa were lower and higher, respectively, than those of healthy subjects with normal body weight. Among those with type 2 diabetes mellitus, obese patients had lower and lean patients higher fasting plasma ghrelin concentrations than normal-weight patients. Fasting plasma ghrelin concentration was negatively correlated with body mass index in both nondiabetic and diabetic patients. Plasma ghrelin concentrations of normal subjects decreased significantly after oral and iv glucose administration; a similar response was also observed in diabetic patients after a meal tolerance test, reaching a nadir of 69% of the basal level after the meal. Circulating plasma ghrelin showed a diurnal pattern with preprandial increases, postprandial decreases, and a maximum peak at 0200 h. This study demonstrates that nutritional state is a determinant of plasma ghrelin in humans. Ghrelin secretion is up-regulated under conditions of negative energy balance and down-regulated in the setting of positive energy balance. These findings suggest the involvement of ghrelin in the regulation of feeding behavior and energy homeostasis.

	Introduction

Top Abstract Introduction Subjects and Methods Results Discussion References

 
MEMBERS OF THE family of seven-transmembrane, G protein-coupled cell surface receptors (GPCRs) respond to a wide variety of signals, including photons, amines, peptides, and proteases. Recent efforts in genomics research have identified a large number of cDNA sequences that encode orphan GPCRs, that is, putative GPCRs without known cognate ligands. We undertook a systematic biochemical search for endogenous peptide ligands of multiple orphan GPCRs, using a cell-based reporter system. These screening experiments led to the identification of a novel peptide that binds to a previously described orphan GPCR (1), the growth-hormone secretagogue receptor. This peptide, called ghrelin, contains 28 amino acids, including an N-octanoylated Ser 3, and was originally discovered in rat and human stomach (2). Ghrelin-producing endocrine cells, which are most abundant in the oxyntic mucosa of both species, account for about 20% of the oxyntic gland endocrine cell population (3, 4). Ghrelin was found to stimulate GH release in vivo and in vitro (2, 5, 6, 7, 8, 9, 10, 11, 12). Ghrelin increased food intake and body weight in rodents when administered centrally and peripherally (11, 12, 13, 14, 15, 16). In contrast, an intracerebroventricular administration of anti-ghrelin IgG robustly suppressed feeding (14). These results suggest a role for ghrelin in the regulation of feeding behavior. We established an RIA for ghrelin and found considerably high plasma concentrations of ghrelin in humans and rats (2, 17, 18). The plasma ghrelin concentration in rats increased upon fasting and returned to baseline after refeeding (4, 13, 18). In this study, to investigate the possible involvement of ghrelin in the regulation of metabolic balance, we measured plasma ghrelin concentrations in patients with simple obesity and anorexia nervosa, and lean and obese patients with type 2 diabetes mellitus (DM). We also studied plasma ghrelin responses to glucose load in normal subjects and to a test meal in diabetic patients. Finally, we investigated the 24-h profile of circulating ghrelin in humans.

	Subjects and Methods

Top Abstract Introduction Subjects and Methods Results Discussion References

 
Subjects

The following groups were studied: 28 healthy controls [14 men and 14 women; mean age ± SEM, 30.4 ± 4.1 yr; body mass index (BMI), 19.8–24.6, mean ± SEM, 22.7 ± 0.4]; 17 patients with anorexia nervosa (1 man and 16 women; 22.2 ± 2.3 yr; BMI, 9.3–17.3, 14.2 ± 0.5); 11 patients with simple obesity (4 men and 7 women; 35.1 ± 3.7 yr; BMI, 26.3–40.5, 30.4 ± 1.2); and 42 patients with type 2 DM without nephropathy (18 men and 24 women; 58.5 ± 1.6 yr; BMI <18.5, n = 4; 18.5 BMI < 25, n = 19; BMI 25, n = 19). Among the anorexia nervosa patients, 9 were of the restricting type and 8 of the binge eating/purging type according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, American Psychiatric Association, 1994. Among the diabetic patients, 12 were treated with diet and exercise, 22 with oral hypoglycemic agents, and 8 with insulin. All subjects were classified into lean (BMI <18.5), normal (18.5 BMI < 25), and obese (BMI 25) categories according to the criteria of the Japan Diabetes Society and Japan Society for the Study of Obesity. All subjects were clinically stable at the time of evaluation and had no evidence of gastrointestinal disease or cachectic states such as cancer, thyroid disease, liver disease, or infection. Patients with renal dysfunction (serum creatinine 1.5 mg/dl) were excluded. Blood was collected at 0800 h after an overnight fast.

Protocol

Healthy volunteers who were within 10% of ideal body weight (9 men and 10 women; 25.3 ± 2.5 yr) were given a 75 g/225 ml glucose solution orally. They also were given 225 ml distilled water orally on a different day. Blood was collected 0, 30, 60, and 120 min after administration. These subjects also were given 10 g/20 ml glucose iv for 2 min. Blood was collected 0, 3, 5, 10, 15, 30, and 60 min after the glucose injection. Seven diabetic patients without triopathy (3 men and 4 women; 52.6 ± 5.6 yr; BMI, 21.3–37.0, 26.0 ± 2.0) were given a test meal (450 cal, 50% carbohydrate, 30% fat, and 20% protein) at 0800 h. Blood was collected 0, 30, 60, and 120 min after eating. For the 24-h monitoring study, 10 healthy men of normal weight (29.6 ± 3.4 yr) were given meals at 0800, 1200, and 1800 h, and blood was collected every 2 h over that 24-h period. Plasma glucose was measured by the glucose oxidase method. Plasma insulin was determined by an RIA kit (Shionogi, Tokyo, Japan). The Institutional Committee of Miyazaki Medical College approved the protocol, and all subjects provided written informed consent before participation.

Ghrelin assay

Blood was drawn into chilled tubes containing EDTA·2Na (1 mg/ml) and aprotinin (500 U/ml). Plasma ghrelin was measured by an RIA developed in our laboratory (17). In brief, antiserum against the C-terminal region of human ghrelin was raised in New Zealand white rabbits that were immunized against synthetic human ghrelin [13–28] that had been coupled with maleimide-activated mariculture keyhole limpet hemocyanin. Human Tyr⁰-ghrelin [13–28] was radioiodinated by the lactoperoxidase method for use in the assay. Inter- and intra-assay variation was less than 8 and 6%, respectively. The limit of detection of this assay is 12 fmol per tube of human ghrelin. Two milliliters of plasma were diluted with 2 ml of 0.9% saline and applied to a Sep-Pak C-18 cartridge (Waters Corp., Milford, MA) pre-equilibrated with 0.9% saline. The cartridge was washed first with saline and then with a 0.1% trifluoroacetic acid solution, and peptides were eluted with a 60% acetonitrile (CH₃CN) solution containing 0.1% trifluoroacetic acid. The eluate was evaporated, reconstituted with RIA buffer, and subjected to RIA analysis. A diluted sample or a standard peptide solution (100 µl) was incubated for 24 h with 100 µl of the antiserum diluent (final dilution, 1:20,000). The tracer solution (16,000 cpm/100 µl) was added, and the mixture was incubated for 24 h. Bound and free ligands were separated by the second antibody method. All procedures were performed at 4 C. Recovery of human ghrelin added to the plasma was 90.7 ± 4.0% (n = 6).

Statistical analyses

Groups of data (mean ± SEM) were compared using ANOVA and a post hoc Fisher’s test. A P value of less than 0.05 was considered statistically significant. Correction coefficients were calculated by linear regression analysis.

	Results

Top Abstract Introduction Subjects and Methods Results Discussion References

 
The antiserum raised against human ghrelin showed no cross-reactivity with human insulin, glucagon, somatostatin, pancreatic polypeptide, neuropeptide Y, or motilin (Fig. 1). A serial dilution curve of a human plasma sample was parallel to a standard curve for human ghrelin (Fig. 1).

View larger version (19K): [in this window] [in a new window]   Figure 1. Standard RIA curve for human ghrelin and cross-reactivity of antiserum. Inhibition of radiolabeled human ghrelin binding by serial dilutions of human ghrelin (), plasma extract (•), and insulin, glucagon, somatostatin, pancreatic polypeptide, neuropeptide Y, and motilin (). The numeral 1 in the plasma dilution curve denotes 2 ml.

View larger version (22K): [in this window] [in a new window]   Figure 2. A, Comparison of plasma ghrelin concentrations in anorexia nervosa patients (BMI <18.5), healthy controls (18.5 BMI < 25), and simple obesity patients (BMI 25). B, Negative correlation between plasma ghrelin concentration and BMI for subjects in A.

View larger version (22K): [in this window] [in a new window]   Figure 3. A, Comparison of plasma ghrelin concentration in lean, normal-weight, and obese type 2 diabetic patients. B, Negative correlation between plasma ghrelin concentration and BMI for diabetic patients in A.

View larger version (17K): [in this window] [in a new window]   Figure 4. A, Plasma ghrelin responses to 75 g oral glucose tolerance test () and oral water load () in normal subjects. *P < 0.0001 in plasma ghrelin vs. 0 min. B, Plasma ghrelin response to 10 g iv glucose tolerance test in normal subjects. *, P < 0.05, **, P < 0.005 in plasma ghrelin vs. 0 min. The results are represented as percentages of the basal level.

View larger version (21K): [in this window] [in a new window]   Figure 5. Plasma ghrelin response to a meal tolerance test in type 2 diabetic patients. *, P < 0.05 vs. 0 min.

View larger version (24K): [in this window] [in a new window]   Figure 6. A 24-h plasma ghrelin profile from normal subjects. Arrows denote meal times.

	Discussion

Top Abstract Introduction Subjects and Methods Results Discussion References

Plasma ghrelin concentrations were higher in patients with anorexia nervosa and lower in patients with simple obesity compared with normal-weight control subjects. Tschöp et al. (19) have measured plasma ghrelin concentrations in normal and obese Caucasian and Pima Indian individuals. They reported that fasting plasma ghrelin concentration negatively correlates with percentage of body fat, and fasting insulin and leptin concentrations. We also found that fasting plasma ghrelin concentration in normal subjects and patients with anorexia nervosa, simple obesity, or type 2 DM correlated negatively with BMI within each group. If the action of ghrelin in humans is similar to that in rodents, ghrelin should stimulate feeding. Anorexia nervosa is an eating disorder in which patients have obsessive ideation about body weight. Reduced feeding in anorexia nervosa patients who have high plasma ghrelin concentrations suggests that they may have decreased sensitivity to circulating ghrelin, or that there may be a central system regulating energy homeostasis that overcomes the effect of ghrelin in such patients. Ghrelin stimulates GH release in humans (7, 8). Nutritional status plays an important role in the regulation of the GH axis, because GH secretion is markedly influenced by body composition (20, 21, 22). Although we did not investigate plasma GH levels in this study, the basal plasma ghrelin concentration probably correlates with that of GH in anorexia nervosa when we take into account the fact that plasma GH is elevated at baseline in this disorder (23, 24).

The stomach is the main source of circulating ghrelin in humans and rats. Ghrelin production in the stomach is localized to A ()-like cells that do not have glucagon-immunoreactivity but share some morphological features with pancreatic -cells, including the presence of compact and dense secretory granules (3). Oral and iv administration of glucose to normal subjects decreased their plasma ghrelin concentrations, whereas intake of an equivalent volume of water did not. Also in rats, stomach filling with water did not change plasma ghrelin level (13). Secretion of ghrelin is not affected by stomach expansion. Insulin-induced hypoglycemia up-regulates ghrelin mRNA expression in the rat stomach (18). Taken together, these results indicate that there may be a system in ghrelin-producing cells that responds to plasma glucose concentration. Molecular signals that regulate ghrelin secretion are not known. Further investigation is needed to define the receptors, transporters, and/or channels expressed in ghrelin-producing cells.

Glucose load and food intake lead to a rapid fall in plasma ghrelin concentration, suggesting that plasma ghrelin reflects an acute feeding state and may also serve as an indicator of short-term energy balance. Plasma ghrelin levels are low in human obesity, and are generally associated with increased weight. Ghrelin mRNA expression in the gastric fundi of db/db mice, an obese model characterized by a null mutation in the leptin receptor gene (25, 26), is down-regulated compared with control mice (18). These alterations of ghrelin expression may be a physiological adaptation to long-term positive energy balance.

The diurnal variation of ghrelin secretion in normal subjects appears to be entrained to meal-taking and sleep. The temporal pattern of plasma ghrelin concentration consists of a rise just before the onset of meals and a postprandial decline during the daytime, followed by a much greater increase culminating at 0200 h. The physiological signals that initiate eating in humans are poorly understood. A preprandial rise in plasma ghrelin concentration suggests that ghrelin may be a candidate for a meal-initiation signal. A 24-h profile of human plasma GH concentration (20, 27) resembles that of ghrelin. Human plasma GH also decreases after meals and peaks at 0200–0300 h. Additional studies are needed to examine the potential link between ghrelin and GH diurnal changes in humans.

In summary, the present study demonstrates that nutritional state is a determinant of plasma ghrelin concentration in humans. Ghrelin secretion is up-regulated under conditions of negative energy balance and down-regulated in the setting of positive energy balance. These findings shed new light upon the involvement of the novel gastrointestinal peptide, ghrelin, in the regulation of feeding behavior and energy homeostasis.

	Acknowledgments

 

	Footnotes

 
This study was supported in part by grants-in-aid from the Ministry of Education, Culture, Sports, Science and Technology, Japan; the Ministry of Health, Labor and Welfare, Japan; the NOVARTIS Foundation (Japan) for the Promotion of Science; the Society of Molecular Mechanism of the Digestive Tract; Mitsui Life Foundation; and The Foundation for Growth Science (to M.N.).

Abbreviations: BMI, Body mass index; DM, diabetes mellitus; GPCR, G protein-coupled cell surface receptor.

Received August 1, 2001.

Accepted September 24, 2001.

	References

Top Abstract Introduction Subjects and Methods Results Discussion References

 

1. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, Paress PS, Diaz C, Chou M, Liu KK, McKee KK, Pong SS, Chaung LY, Elbrecht A, Dashkevicz M, Heavens R, Rigby M, Sirinathsinghji DJ, Dean DC, Melillo DG, Patchet AA, Nargund R, Griffin PR, DeMartino JA, Gupta SK, Schaeffer JM, Smith RG, Van der Ploeg LH 1996 A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 273:974–977[Abstract]
2. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K 1999 Ghrelin is a novel growth-hormone-releasing acylated peptide from stomach. Nature 402:656–660[CrossRef][Medline]
3. Date Y, Kojima M, Hosoda H, Sawaguchi A, Mondal MS, Suganuma T, Matsukura S, Kangawa K, Nakazato M 2000 Ghrelin, a novel growth hormone-releasing acylated peptide, is synthesized in a distinct endocrine cell type in the gastrointestinal tracts of rats and humans. Endocrinology 141:4255–4261[Abstract/Free Full Text]
4. Dornonville de la Cour C, Björkqvist M, Sandvik AK, Bakke I, Zhao CM, Chen D, Hakanson R 2001 A-like cells in the rat stomach contain ghrelin and do not operate under gastrin control. Regul Pept 99: 141–150
5. Date Y, Murakami N, Kojima M, Kuroiwa T, Matsukura S, Kangawa K, Nakazato M 2000 Central effects of a novel acylated peptide, ghrelin, on growth hormone release in rats. Biochem Biophys Res Commun 275:477–480[CrossRef][Medline]
6. Seoane LM, Tovar S, Baldelli R, Arvat E, Ghigo E, Casanueva FF, Dieguez C 2000 Ghrelin elicits a marked stimulatory effect on GH secretion in free-moving rats. Eur J Endocrinol 143:R7–R9
7. Peino R, Baldelli R, Rodriguez-Garcia J, Rodriguez-Segade S, Kojima M, Kangawa K, Arvat E, Ghigo E, Dieguez C, Casanueva FF 2000 Ghrelin-induced growth hormone secretion in humans. Eur J Endocrinol 143:R11–R14
8. Takaya K, Ariyasu H, Kanamoto N, Iwakura H, Yoshimoto A, Harada M, Mori K, Komatsu Y, Usui T, Shimatsu A, Ogawa Y, Hosoda K, Akamizu T, Kojima M, Kangawa K, Nakao K 2000 Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab 85:4908–4911[Abstract/Free Full Text]
9. Tolle V, Zizzari P, Tomasetto C, Rio MC, Epelbaum J, Bluet-Pajot MT 2001 In vivo and in vitro effects of ghrelin/motilin-related peptide on growth hormone secretion in the rat. Neuroendocrinology 73:54–61[CrossRef][Medline]
10. Bowers CY 2001 Unnatural growth hormone-releasing peptide begets natural ghrelin. J Clin Endocrinol Metab 86:1464–1469[Free Full Text]
11. Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S, Kennedy AR, Roberts GH, Morgan DG, Ghatei MA, Bloom SR 2000 The novel hypothalamic peptide ghrelin stimulates food intake and GH secretion. Endocrinology 141:4325–4328[Abstract/Free Full Text]
12. Kamegai J, Tamura H, Shimizu T, Ishii S, Sugihara H, Wakabayashi I 2000 Central effect of ghrelin, an endogenous growth hormone secretagogue, on hypothalamic peptide gene expression. Endocrinology 141:4797–4800[Abstract/Free Full Text]
13. Tschöp M, Smiley DL, Heiman ML 2000 Ghrelin induces adiposity in rodents. Nature 407:908–913[CrossRef][Medline]
14. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S 2001 A role for ghrelin in the central regulation of feeding. Nature 409:194–198[CrossRef][Medline]
15. Asakawa A, Inui A, Kaga T, Yuzuriha H, Nagata T, Ueno N, Makino S, Fujimiya M, Niijima A, Fujino MA, Kasuga M 2001 Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 120:337–345[CrossRef][Medline]
16. Shintani M, Ogawa Y, Ebihara K, Aizawa-Abe M, Miyanaga F, Takaya K, Hayashi T, Inoue G, Hosoda K, Kojima M, Kangawa K, Nakao K 2001 Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 50:227–232[Abstract/Free Full Text]
17. Hosoda H, Kojima M, Matsuo H, Kangawa K 2000 Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun 279:909–913[CrossRef][Medline]
18. Toshinai K, Mondal MS, Nakazato M, Date Y, Murakami N, Kojima M, Kangawa K, Matsukura S 2001 Upregulation of ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration. Biochem Biophys Res Commun 281:1220–1225[CrossRef][Medline]
19. Tschöp M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML 2001 Circulating ghrelin levels are decreased in human obesity. Diabetes 50:707–709[Abstract/Free Full Text]
20. Ho KY, Veldhuis JD, Johnson ML, Furlanetto R, Evans WS, Alberti KG, Thorner MO 1988 Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. J Clin Invest 81:968–975
21. Patel L, Skinner AM, Price DA, Clayton PE 1994 The influence of body mass index on growth hormone secretion in normal and short statured children. Growth Regul 4:29–34[Medline]
22. Jorgensen JO, Vahl N, Hansen TB, Fisker S, Hagen C, Christiansen JS 1996 Influence of growth hormone and androgens on body composition in adults. Horm Res 45:94–98[Medline]
23. Macaron C, Wilber JF, Green O, Freinkel N 1978 Studies of growth hormone (GH), thyrotropin (TSH) and prolactin (PRL) secretion in anorexia nervosa. Psychoneuroendocrinology 2:181–185[CrossRef]
24. De Marinis L, Folli G, D’Amico C, Mancini A, Sambo P, Tofani A, Oradei A, Barbarino A 1988 Differential effects of feeding on the ultradian variation of the growth hormone (GH) response to GH-releasing hormone in normal subjects and patients with obesity and anorexia nervosa. J Clin Endocrinol Metab 66:598–604[Abstract]
25. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, Moore KJ, Breitbart RE, Duyk GM, Tepper RI, Morgenstern JP 1996 Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 84:491–495[CrossRef][Medline]
26. Chua Jr SC, Chung WK, Wu-Peng XS, Zhang Y, Liu SM, Tartaglia L, Leibel RL 1996 Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science 271:994–996[Abstract]
27. Hartman ML, Veldhuis JD, Johnson ML, Lee MM, Alberti KG, Samojlik E, Thorner MO 1992 Augmented growth hormone (GH) secretory burst frequency and amplitude mediate enhanced GH secretion during a two-day fast in normal men. J Clin Endocrinol Metab 74:757–765[Abstract]

This article has been cited by other articles:

				C. Maier, M. Riedl, G. Vila, P. Nowotny, M. Wolzt, M. Clodi, B. Ludvik, and A. Luger Cholinergic Regulation of Ghrelin and Peptide YY Release May Be Impaired in Obesity Diabetes, September 1, 2008; 57(9): 2332 - 2340. [Abstract] [Full Text] [PDF]

				M. S Mondal, K. Toshinai, H. Ueno, K. Koshinaka, and M. Nakazato Characterization of obestatin in rat and human stomach and plasma, and its lack of acute effect on feeding behavior in rodents J. Endocrinol., August 1, 2008; 198(2): 339 - 346. [Abstract] [Full Text] [PDF]

				X. Xu, B. Sook Jhun, C. Hoon Ha, and Z.-G. Jin Molecular Mechanisms of Ghrelin-Mediated Endothelial Nitric Oxide Synthase Activation Endocrinology, August 1, 2008; 149(8): 4183 - 4192. [Abstract] [Full Text] [PDF]

				A. Geliebter, C. N. Ochner, and R. Aviram-Friedman Appetite-Related Gut Peptides in Obesity and Binge Eating Disorder American Journal of Lifestyle Medicine, July 1, 2008; 2(4): 305 - 314. [Abstract] [PDF]

				K Scrimgeour, M J Gresham, L R Giles, P C Thomson, P C Wynn, and R E Newman Ghrelin secretion is more closely aligned to energy balance than with feeding behaviour in the grower pig J. Endocrinol., July 1, 2008; 198(1): 135 - 145. [Abstract] [Full Text] [PDF]

				L. Dossus, J. D. McKay, F. Canzian, S. Wilkening, S. Rinaldi, C. Biessy, A. Olsen, A. Tjonneland, M. U. Jakobsen, K. Overvad, et al. Polymorphisms of genes coding for ghrelin and its receptor in relation to anthropometry, circulating levels of IGF-I and IGFBP-3, and breast cancer risk: a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) Carcinogenesis, July 1, 2008; 29(7): 1360 - 1366. [Abstract] [Full Text] [PDF]

				U. Mager, M. Kolehmainen, V. D F de Mello, U. Schwab, D. E Laaksonen, R. Rauramaa, H. Gylling, M. Atalay, L. Pulkkinen, and M. Uusitupa Expression of ghrelin gene in peripheral blood mononuclear cells and plasma ghrelin concentrations in patients with metabolic syndrome. Eur. J. Endocrinol., April 1, 2008; 158(4): 499 - 510. [Abstract] [Full Text] [PDF]

				T. M Barber, F. F Casanueva, F. Karpe, M. Lage, S. Franks, M. I McCarthy, and J. A H Wass Ghrelin levels are suppressed and show a blunted response to oral glucose in women with polycystic ovary syndrome. Eur. J. Endocrinol., April 1, 2008; 158(4): 511 - 516. [Abstract] [Full Text] [PDF]

				J. J. Diez, J. L. Miguel, R. Codoceo, P. Iglesias, M. A. Bajo, C. Sanchez, G. del Peso, F. Gil, J. Martinez-Ara, P. G. Gancedo, et al. Effects of cinacalcet on gastrointestinal hormone release in patients with secondary hyperparathyroidism undergoing dialysis Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1387 - 1395. [Abstract] [Full Text] [PDF]

				A. J. Smeets, S. Soenen, N. D. Luscombe-Marsh, O. Ueland, and M. S. Westerterp-Plantenga Energy Expenditure, Satiety, and Plasma Ghrelin, Glucagon-Like Peptide 1, and Peptide Tyrosine-Tyrosine Concentrations following a Single High-Protein Lunch J. Nutr., April 1, 2008; 138(4): 698 - 702. [Abstract] [Full Text] [PDF]

				J. R. Roche, A. J. Sheahan, L. M. Chagas, and R. C. Boston Short Communication: Change in Plasma Ghrelin in Dairy Cows Following an Intravenous Glucose Challenge J Dairy Sci, March 1, 2008; 91(3): 1005 - 1010. [Abstract] [Full Text] [PDF]

				J. M. Frecka and R. D. Mattes Possible entrainment of ghrelin to habitual meal patterns in humans Am J Physiol Gastrointest Liver Physiol, March 1, 2008; 294(3): G699 - G707. [Abstract] [Full Text] [PDF]

				C. Chiesa, J. F. Osborn, C. Haass, F. Natale, M. Spinelli, E. Scapillati, A. Spinelli, and L. Pacifico Ghrelin, Leptin, IGF-1, IGFBP-3, and Insulin Concentrations at Birth: Is There a Relationship with Fetal Growth and Neonatal Anthropometry? Clin. Chem., March 1, 2008; 54(3): 550 - 558. [Abstract] [Full Text] [PDF]

				E. Lanyi, A. Varnagy, K. A Kovacs, T. Csermely, M. Szasz, and I. Szabo Ghrelin and acyl ghrelin in preterm infants and maternal blood: relationship with endocrine and anthropometric measures Eur. J. Endocrinol., January 1, 2008; 158(1): 27 - 33. [Abstract] [Full Text] [PDF]

				N. Alonso, M. L. Granada, I. Salinas, J. L. Reverter, L. Flores, I. Ojanguren, E. M. Martinez-Caceres, and A. Sanmarti Plasma ghrelin concentrations in type 1 diabetic patients with autoimmune atrophic gastritis Eur. J. Endocrinol., December 1, 2007; 157(6): 763 - 769. [Abstract] [Full Text] [PDF]

				T. J Little, M. Horowitz, and C. Feinle-Bisset Modulation by high-fat diets of gastrointestinal function and hormones associated with the regulation of energy intake: implications for the pathophysiology of obesity Am. J. Clinical Nutrition, September 1, 2007; 86(3): 531 - 541. [Abstract] [Full Text] [PDF]

				H. Takahashi, Y. Kurose, M. Sakaida, Y. Suzuki, S. Kobayashi, T. Sugino, M. Kojima, K. Kangawa, Y. Hasegawa, and Y. Terashima Ghrelin differentially modulates glucose-induced insulin secretion according to feeding status in sheep J. Endocrinol., September 1, 2007; 194(3): 621 - 625. [Abstract] [Full Text] [PDF]

				T. Ando, Y. Ichimaru, F. Konjiki, M. Shoji, and G. Komaki Variations in the preproghrelin gene correlate with higher body mass index, fat mass, and body dissatisfaction in young Japanese women Am. J. Clinical Nutrition, July 1, 2007; 86(1): 25 - 32. [Abstract] [Full Text] [PDF]

				D. R. Broom, D. J. Stensel, N. C. Bishop, S. F. Burns, and M. Miyashita Exercise-induced suppression of acylated ghrelin in humans J Appl Physiol, June 1, 2007; 102(6): 2165 - 2171. [Abstract] [Full Text] [PDF]

				Z.-F. Guo, X. Zheng, Y.-W. Qin, J.-Q. Hu, S.-P. Chen, and Z. Zhang Circulating Preprandial Ghrelin to Obestatin Ratio Is Increased in Human Obesity J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1875 - 1880. [Abstract] [Full Text] [PDF]

				C. De Vriese, M. Hacquebard, F. Gregoire, Y. Carpentier, and C. Delporte Ghrelin Interacts with Human Plasma Lipoproteins Endocrinology, May 1, 2007; 148(5): 2355 - 2362. [Abstract] [Full Text] [PDF]

				B. P. Hauffa, K. Haase, I. M. Range, N. Unger, K. Mann, and S. Petersenn The Effect of Growth Hormone on the Response of Total and Acylated Ghrelin to a Standardized Oral Glucose Load and Insulin Resistance in Children with Prader-Willi Syndrome J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 834 - 840. [Abstract] [Full Text] [PDF]

				D. G. Haider, K. Schindler, G. Prager, A. Bohdjalian, A. Luger, M. Wolzt, and B. Ludvik Serum Retinol-Binding Protein 4 Is Reduced after Weight Loss in Morbidly Obese Subjects J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 1168 - 1171. [Abstract] [Full Text] [PDF]

				P. Clerc, M. G. Coll Constans, H. Lulka, S. Broussaud, C. Guigne, S. Leung-Theung-Long, C. Perrin, C. Knauf, C. Carpene, L. Penicaud, et al. Involvement of Cholecystokinin 2 Receptor in Food Intake Regulation: Hyperphagia and Increased Fat Deposition in Cholecystokinin 2 Receptor-Deficient Mice Endocrinology, March 1, 2007; 148(3): 1039 - 1049. [Abstract] [Full Text] [PDF]

				M. Iantorno, H. Chen, J.-a Kim, M. Tesauro, D. Lauro, C. Cardillo, and M. J. Quon Ghrelin has novel vascular actions that mimic PI 3-kinase-dependent actions of insulin to stimulate production of NO from endothelial cells Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E756 - E764. [Abstract] [Full Text] [PDF]

				R. M. Luque, Z. H. Huang, B. Shah, T. Mazzone, and R. D. Kineman Effects of leptin replacement on hypothalamic-pituitary growth hormone axis function and circulating ghrelin levels in ob/ob mice Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E891 - E899. [Abstract] [Full Text] [PDF]

				A. S Bang, S. G Soule, T. G Yandle, A M. Richards, and C. J Pemberton Characterisation of proghrelin peptides in mammalian tissue and plasma J. Endocrinol., February 1, 2007; 192(2): 313 - 323. [Abstract] [Full Text] [PDF]

				H. Chung, E. Kim, D. H. Lee, S. Seo, S. Ju, D. Lee, H. Kim, and S. Park Ghrelin Inhibits Apoptosis in Hypothalamic Neuronal Cells during Oxygen-Glucose Deprivation Endocrinology, January 1, 2007; 148(1): 148 - 159. [Abstract] [Full Text] [PDF]

				K. Dezaki, H. Sone, M. Koizumi, M. Nakata, M. Kakei, H. Nagai, H. Hosoda, K. Kangawa, and T. Yada Blockade of Pancreatic Islet-Derived Ghrelin Enhances Insulin Secretion to Prevent High-Fat Diet-Induced Glucose Intolerance Diabetes, December 1, 2006; 55(12): 3486 - 3493. [Abstract] [Full Text] [PDF]

				A. E. Wertz-Lutz, T. J. Knight, R. H. Pritchard, J. A. Daniel, J. A. Clapper, A. J. Smart, A. Trenkle, and D. C. Beitz Circulating ghrelin concentrations fluctuate relative to nutritional status and influence feeding behavior in cattle J Anim Sci, December 1, 2006; 84(12): 3285 - 3300. [Abstract] [Full Text] [PDF]

				E. Naslund and J. G. Kral Impact of Gastric Bypass Surgery on Gut Hormones and Glucose Homeostasis in Type 2 Diabetes Diabetes, December 1, 2006; 55(Supplement_2): S92 - S97. [Abstract] [Full Text] [PDF]

				Y. P Lee, T. A Mori, S. Sipsas, A. Barden, I. B Puddey, V. Burke, R. S Hall, and J. M Hodgson Lupin-enriched bread increases satiety and reduces energy intake acutely. Am. J. Clinical Nutrition, November 1, 2006; 84(5): 975 - 980. [Abstract] [Full Text] [PDF]